Benevolent is an AI-powered life sciences company developing advanced computational platforms for drug discovery and development. The company integrates artificial intelligence with biomedical expertise to analyze large-scale medical datasets and generate actionable insights for pharmaceutical research.
Benevolent operates at the intersection of generative AI and biotechnology, aiming to reduce the time, cost, and failure rate of traditional drug development.
What Is Benevolent and What Does It Do?
Benevolent, founded in 2013, is a London-based artificial intelligence company specializing in drug discovery and development. The company builds AI-driven platforms that combine machine learning with scientific judgment to interpret complex biomedical data.
Its judgement-augmented correlation system helps identify disease pathways, therapeutic targets, and drug candidates. Benevolent develops its own internal drug programs while also supporting pharmaceutical research through its technology platform.
Benevolent employs 105 employees as of December 2023 and operates within the generative AI and life sciences technology ecosystem.
How Much Funding Has Benevolent Raised?
1. Series C
- Amount Raised: $90M
- Date: May 2019
- Motivation: To advance AI-driven drug discovery programs, expand therapeutic pipelines, and strengthen platform capabilities.
Total Funding Raised: $282 Million
Latest Funding Date: May, 2019
Key Investors
1. State Street
- Details: A global investment management firm with exposure to public and private growth-stage companies.
- Investment Focus Areas: Asset management, public equities, alternative investments.
- Notable Investments: Benevolent.
2. Schonfeld Strategic Advisors
- Details: A multi-strategy investment firm operating across public and private markets worldwide.
- Investment Focus Areas: Technology, healthcare, data-driven investment strategies.
- Notable Investments: Benevolent.
Where Is Benevolent’s Headquarters?
Benevolent is headquartered in London, United Kingdom, benefiting from proximity to leading research institutions, pharmaceutical partners, and global life sciences talent.
What’s Next for Benevolent?
Benevolent is focused on advancing its internal drug discovery pipeline while continuing to refine its AI platform for deeper biological insights. The company is expected to prioritize clinical progress, strategic collaborations, and disciplined capital deployment as it operates in public markets.
With continued investment in generative AI and biomedical research, Benevolent aims to strengthen its position as a leading AI-native drug discovery company.
Get Investor & Funding Insights with TexAu
TexAu helps sales and business teams uncover detailed fundraising information on companies like Benevolent. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.
Sign Up for Free on TexAu and start uncovering detailed funding insights that give your business a competitive edge.